Cargando…
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521209/ https://www.ncbi.nlm.nih.gov/pubmed/35734925 http://dx.doi.org/10.3324/haematol.2022.280660 |
| _version_ | 1784799791780200448 |
|---|---|
| author | Martin, Tom Richardson, Paul G. Facon, Thierry Moreau, Philippe Perrot, Aurore Spicka, Ivan Bisht, Kamlesh Inchauspé, Marlene Casca, France Macé, Sandrine van de Velde, Helgi Suzuki, Kenshi |
| author_facet | Martin, Tom Richardson, Paul G. Facon, Thierry Moreau, Philippe Perrot, Aurore Spicka, Ivan Bisht, Kamlesh Inchauspé, Marlene Casca, France Macé, Sandrine van de Velde, Helgi Suzuki, Kenshi |
| author_sort | Martin, Tom |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9521209 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95212092022-10-24 Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA Martin, Tom Richardson, Paul G. Facon, Thierry Moreau, Philippe Perrot, Aurore Spicka, Ivan Bisht, Kamlesh Inchauspé, Marlene Casca, France Macé, Sandrine van de Velde, Helgi Suzuki, Kenshi Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-06-23 /pmc/articles/PMC9521209/ /pubmed/35734925 http://dx.doi.org/10.3324/haematol.2022.280660 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Martin, Tom Richardson, Paul G. Facon, Thierry Moreau, Philippe Perrot, Aurore Spicka, Ivan Bisht, Kamlesh Inchauspé, Marlene Casca, France Macé, Sandrine van de Velde, Helgi Suzuki, Kenshi Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title | Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title_full | Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title_fullStr | Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title_full_unstemmed | Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title_short | Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA |
| title_sort | primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from icaria-mm and ikema |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521209/ https://www.ncbi.nlm.nih.gov/pubmed/35734925 http://dx.doi.org/10.3324/haematol.2022.280660 |
| work_keys_str_mv | AT martintom primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT richardsonpaulg primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT faconthierry primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT moreauphilippe primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT perrotaurore primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT spickaivan primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT bishtkamlesh primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT inchauspemarlene primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT cascafrance primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT macesandrine primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT vandeveldehelgi primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema AT suzukikenshi primaryoutcomesby1q21statusforisatuximabtreatedpatientswithrelapsedrefractorymultiplemyelomasubgroupanalysesfromicariammandikema |